How many insider trades does FilingIQ track for OKYO?

FilingIQ tracks 19 Form 4 insider transactions for OKYO (OKYO Pharma Ltd), covering filings from May 17, 2022 onwards. 11 of those were filed in the last 90 days.

Are OKYO insiders net buyers or net sellers?

Across the full Form 4 history for OKYO, 6 transactions (32%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does OKYO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is OKYO in?

OKYO Pharma Ltd (OKYO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $82.39M.

OKYO insider trading

NasdaqCM Healthcare

OKYO Pharma Ltd — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

32% / 0%

Market cap

$82.39M

About OKYO Pharma Ltd

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Company website: okyopharma.com

OKYO insider activity at a glance

FilingIQ has scored 19 insider transactions for OKYO since May 17, 2022. The most recent filing in our index is dated Jul 22, 2026.

Across the full history, 6 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on OKYO insider trades is 65.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live OKYO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,061

UNITED THERAPEUTICS Corp

APLS 271

Apellis Pharmaceuticals, Inc.

NUVL 209

Nuvalent, Inc.

KYMR 200

Kymera Therapeutics, Inc.

GH 189

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for OKYO?: FilingIQ tracks 19 Form 4 insider transactions for OKYO (OKYO Pharma Ltd), covering filings from May 17, 2022 onwards. 11 of those were filed in the last 90 days.
Are OKYO insiders net buyers or net sellers?: Across the full Form 4 history for OKYO, 6 transactions (32%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does OKYO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is OKYO in?: OKYO Pharma Ltd (OKYO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $82.39M.

Methodology & sources

Every OKYO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.